Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZeping ZhouXLXinxiao LuLYLinyu Yuan

Discussion

Loading...

Member takes

Overview

Phase II trial shows 90.5% overall response rate after induction therapy with Venetoclax and Decitabine in adults with AML, suggesting effective treatment.

Key Points

  • To evaluate the efficacy and safety of Venetoclax combined with Decitabine as induction therapy for adult patients with de novo AML.
  • Single-arm prospective clinical trial in China
  • Enrolled adults aged 16-65 with de novo AML
  • Induction regimen included Venetoclax and Decitabine administration
  • Primary endpoint was overall response rate after one cycle of therapy
  • 95 patients received DEC3-VEN induction chemotherapy
  • 90.5% overall response rate after one cycle of therapy
  • Complete remission rate of 85.2%
  • 80.2% minimal residual disease negativity rate among those with complete remission
  • Adverse effects included neutropenia and febrile neutropenia

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3bdhttps://doi.org/10.1182/blood-2025-1675
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  2. 2Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  3. 3Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion2025 · 1 citations
  4. 4Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.2026
  5. 5Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025